Jeff Yass’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $30.4M | Sell |
114,100
-191,400
| -63% | -$44.7M | ﹤0.01% | 2000 |
|
|
2026
Q1 | $69.9M | Buy |
305,500
+108,700
| +55% | +$24.4M | 0.01% | 1043 |
|
|
2025
Q4 | $42M | Buy |
196,800
+79,900
| +68% | +$16.5M | ﹤0.01% | 1519 |
|
|
2025
Q3 | $23.2M | Buy |
116,900
+71,200
| +156% | +$13.3M | ﹤0.01% | 2043 |
|
|
2025
Q2 | $7.89M | Sell |
45,700
-17,400
| -28% | -$2.83M | ﹤0.01% | 3188 |
|
|
2025
Q1 | $9.83M | Buy |
63,100
+33,700
| +115% | +$4.81M | ﹤0.01% | 2560 |
|
|
2024
Q4 | $4.05M | Sell |
29,400
-91,900
| -76% | -$12.1M | ﹤0.01% | 3926 |
|
|
2024
Q3 | $18.1M | Buy |
121,300
+41,800
| +53% | +$5.64M | ﹤0.01% | 1932 |
|
|
2024
Q2 | $10.8M | Buy |
79,500
+12,400
| +18% | +$1.69M | ﹤0.01% | 2381 |
|
|
2024
Q1 | $10.1M | Sell |
67,100
-11,400
| -15% | -$1.63M | ﹤0.01% | 2582 |
|
|
2023
Q4 | $9.89M | Buy |
78,500
+44,000
| +128% | +$4.39M | ﹤0.01% | 2659 |
|
|
2023
Q3 | $3.23M | Sell |
34,500
-23,000
| -40% | -$2.15M | ﹤0.01% | 4254 |
|
|
2023
Q2 | $5.13M | Sell |
57,500
-222,100
| -79% | -$19.3M | ﹤0.01% | 3487 |
|
|
2023
Q1 | $30M | Buy |
279,600
+125,400
| +81% | +$14.3M | 0.01% | 1319 |
|
|
2022
Q4 | $18.8M | Buy |
154,200
+125,200
| +432% | +$14.5M | ﹤0.01% | 1584 |
|
|
2022
Q3 | $3M | Sell |
29,000
-66,200
| -70% | -$6.28M | ﹤0.01% | 4097 |
|
|
2022
Q2 | $8.85M | Buy |
95,200
+13,600
| +17% | +$1.28M | ﹤0.01% | 2374 |
|
|
2022
Q1 | $9.58M | Buy |
81,600
+72,500
| +797% | +$8.4M | ﹤0.01% | 2606 |
|
|
2021
Q4 | $1.22M | Sell |
9,100
-18,900
| -68% | -$2.81M | ﹤0.01% | 6738 |
|
|
2021
Q3 | $4.46M | Sell |
28,000
-8,700
| -24% | -$1.19M | ﹤0.01% | 4168 |
|
|
2021
Q2 | $4.83M | Buy |
36,700
+10,900
| +42% | +$1.45M | ﹤0.01% | 4099 |
|
|
2021
Q1 | $3.33M | Buy |
25,800
+18,400
| +249% | +$2.8M | ﹤0.01% | 4739 |
|
|
2020
Q4 | $1.23M | Sell |
7,400
-22,000
| -75% | -$3.64M | ﹤0.01% | 6206 |
|
|
2020
Q3 | $4.54M | Sell |
29,400
-86,600
| -75% | -$12.4M | ﹤0.01% | 3185 |
|
|
2020
Q2 | $17.2M | Buy |
116,000
+34,200
| +42% | +$4.7M | ﹤0.01% | 1569 |
|
|
2020
Q1 | $9.21M | Sell |
81,800
-94,200
| -54% | -$12.2M | ﹤0.01% | 1823 |
|
|
2019
Q4 | $24.5M | Sell |
176,000
-218,900
| -55% | -$24.3M | 0.01% | 1247 |
|
|
2019
Q3 | $38M | Sell |
394,900
-47,100
| -11% | -$5.25M | 0.01% | 902 |
|
|
2019
Q2 | $50.9M | Sell |
442,000
-372,600
| -46% | -$44.6M | 0.02% | 678 |
|
|
2019
Q1 | $95.9M | Buy |
814,600
+386,400
| +90% | +$33.8M | 0.04% | 382 |
|
|
2018
Q4 | $26.8M | Buy |
428,200
+393,700
| +1,141% | +$24.7M | 0.01% | 905 |
|
|
2018
Q3 | $2.44M | Buy |
34,500
+3,800
| +12% | +$262K | ﹤0.01% | 3682 |
|
|
2018
Q2 | $2.04M | Buy |
+30,700
| New | +$2.02M | ﹤0.01% | 3983 |
|
Other funds holding ASND
RCM
ACA
JT
Jeff Yass's ASND Position: Q2 2026 in Review
Jeff Yass reduced its Ascendis Pharma A/S (ASND) stake by 96% in Q2 2026, selling an estimated $6.27M and leaving 1,215 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #10874.
Jeff Yass first reported a position in ASND in Q2 2018 and has held it in 25 quarters since. The position peaked at $100M in Q4 2025. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Jeff Yass held 1,215 shares of Ascendis Pharma A/S worth $324K as of Q2 2026.
- Jeff Yass sold 26,847 Ascendis Pharma A/S shares in Q2 2026, an estimated $6.27M.
- Ascendis Pharma A/S made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10874 holding.
- Jeff Yass first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 25 quarters since.
- Jeff Yass's Ascendis Pharma A/S position peaked at $100M in Q4 2025.
- 310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.